Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: European Surgery 6/2020

01.10.2020 | review

Sentinel lymph node biopsy in breast cancer—an updated overview

verfasst von: Dr. Omar Hamdy, Omar Farouk, Adel El-Badrawy, Adel Denewer, Ahmed Setit

Erschienen in: European Surgery | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Sentinel lymphadenectomy has replaced axillary lymph node dissection as a staging tool in early breast cancer. To be accepted as a standard of care, it had to pass successfully through a long journey which started in the early 1990s.

Methods

We carried out a comprehensive literature review focusing on the journey of the use of sentinel lymph node biopsy (SLNB) in breast cancer from its start until its current station, including the variable clinical applications, the current debates, and the future issues.

Results

Adoption of sentinel lymph node biopsy as a standard axillary staging procedure was a marvelous trend that helped to decrease the complications of axillary dissection and significantly improve the quality of life of patients with breast cancer. Various mapping techniques can be used for SLN localization, rendering oncology centers that have variable capabilities and preparations able to perform the procedure. This applies to specimen processing techniques as well. Many debates faced the researchers throughout the SLNB journey. They are all explained in the current article, in addition to the ongoing trials and the future aspects of SLNB in breast cancer.

Conclusion

Further research should be conducted to help resolve the clinical issues which are still debatable and to provide bases for improving the future trends which are progressing towards limiting the role of axillary dissection and axillary surgery to the minimum required level.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
2.
Zurück zum Zitat He Z, Zhou Y, Wang F, Xu Q, Zhang W, Ni X, et al. Clinical value of postoperative sentinel lymph node biopsy. Ann Transl Med. 2019;7:683. PubMedPubMedCentral He Z, Zhou Y, Wang F, Xu Q, Zhang W, Ni X, et al. Clinical value of postoperative sentinel lymph node biopsy. Ann Transl Med. 2019;7:683. PubMedPubMedCentral
3.
Zurück zum Zitat Tsujimoto M. Recent advances in sentinel node biopsy in breast surgery. Breast Cancer. 2015;22:211. PubMed Tsujimoto M. Recent advances in sentinel node biopsy in breast surgery. Breast Cancer. 2015;22:211. PubMed
4.
Zurück zum Zitat Kuru B. The adventure of axillary treatment in early stage breast cancer. Turkish Federation of Breast Diseases Associations. Eur J Breast Health. 2020;16:1–15. PubMedPubMedCentral Kuru B. The adventure of axillary treatment in early stage breast cancer. Turkish Federation of Breast Diseases Associations. Eur J Breast Health. 2020;16:1–15. PubMedPubMedCentral
5.
Zurück zum Zitat Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “sentinel node” in cancer of the parotid. Cancer. 1960;13:77–8. PubMed Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “sentinel node” in cancer of the parotid. Cancer. 1960;13:77–8. PubMed
6.
Zurück zum Zitat Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–66. PubMed Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–66. PubMed
8.
Zurück zum Zitat Morton DL, Wen D‑R, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9. PubMed Morton DL, Wen D‑R, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9. PubMed
9.
Zurück zum Zitat Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391. PubMedPubMedCentral Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391. PubMedPubMedCentral
11.
Zurück zum Zitat Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–401. PubMedPubMedCentral Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–401. PubMedPubMedCentral
12.
Zurück zum Zitat Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271–8. PubMedPubMedCentral Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271–8. PubMedPubMedCentral
14.
Zurück zum Zitat Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–13. PubMed Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–13. PubMed
15.
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983–90. PubMed Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983–90. PubMed
16.
Zurück zum Zitat Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312–21. PubMed Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312–21. PubMed
17.
Zurück zum Zitat Ung OA. Australasian experience and trials in sentinel lymph node biopsy: the RACS SNAC trial. Asian J Surg. 2004;27:284–90. PubMed Ung OA. Australasian experience and trials in sentinel lymph node biopsy: the RACS SNAC trial. Asian J Surg. 2004;27:284–90. PubMed
18.
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53. PubMed Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53. PubMed
19.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B‑32 randomised phase III trial. Lancet Oncol. 2007;8:881–8. PubMed Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B‑32 randomised phase III trial. Lancet Oncol. 2007;8:881–8. PubMed
20.
Zurück zum Zitat Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609. PubMed Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609. PubMed
21.
Zurück zum Zitat Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462. PubMedPubMedCentral Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462. PubMedPubMedCentral
22.
Zurück zum Zitat Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20:1001–7. PubMed Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20:1001–7. PubMed
24.
Zurück zum Zitat Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600. PubMed Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600. PubMed
26.
Zurück zum Zitat Van der Ploeg IMC, Nieweg OE, Van Rijk MC, Olmos RAV, Kroon BBR. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–84. PubMed Van der Ploeg IMC, Nieweg OE, Van Rijk MC, Olmos RAV, Kroon BBR. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–84. PubMed
29.
Zurück zum Zitat Bernardi S, Bertozzi S, Londero AP, Angione V, Petri R, Giacomuzzi F. Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer. Nucl Med Commun. 2013;34:664–73. PubMed Bernardi S, Bertozzi S, Londero AP, Angione V, Petri R, Giacomuzzi F. Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer. Nucl Med Commun. 2013;34:664–73. PubMed
30.
Zurück zum Zitat Dordea M, Colvin H, Cox P, Nicolas AP, Kanakala V, Iwuchukwu O. Clinical and histopathological factors affecting failed sentinel node localization in axillary staging for breast cancer. Surgeon. 2013;11:63–6. PubMed Dordea M, Colvin H, Cox P, Nicolas AP, Kanakala V, Iwuchukwu O. Clinical and histopathological factors affecting failed sentinel node localization in axillary staging for breast cancer. Surgeon. 2013;11:63–6. PubMed
31.
Zurück zum Zitat Nowikiewicz T, Kurylcio A, Polkowski W, Zegarski W. Imaging methods for the local lymphatic system of the axilla in early breast cancer in patients qualified for sentinel lymph node biopsy. Prz Menopauzalny. 2016;15:52. PubMedPubMedCentral Nowikiewicz T, Kurylcio A, Polkowski W, Zegarski W. Imaging methods for the local lymphatic system of the axilla in early breast cancer in patients qualified for sentinel lymph node biopsy. Prz Menopauzalny. 2016;15:52. PubMedPubMedCentral
34.
Zurück zum Zitat Nandu VV, Chaudhari MS. Efficacy of sentinel lymph node biopsy in detecting axillary metastasis in breast cancer using methylene blue. Indian J Surg Oncol. 2017;8:109–12. PubMed Nandu VV, Chaudhari MS. Efficacy of sentinel lymph node biopsy in detecting axillary metastasis in breast cancer using methylene blue. Indian J Surg Oncol. 2017;8:109–12. PubMed
37.
Zurück zum Zitat Wu X, Lin Q, Chen G, Lu J, Zeng Y, Chen X, et al. Sentinel lymph node detection using carbon nanoparticles in patients with early breast cancer. Plos One. 2015;10:e135714–e135714. PubMedPubMedCentral Wu X, Lin Q, Chen G, Lu J, Zeng Y, Chen X, et al. Sentinel lymph node detection using carbon nanoparticles in patients with early breast cancer. Plos One. 2015;10:e135714–e135714. PubMedPubMedCentral
42.
Zurück zum Zitat Petropoulou T, Kapoula A, Mastoraki A, Politi A, Spanidou-Karvouni E, Psychogios I, et al. Imprint cytology versus frozen section analysis for intraoperative assessment of sentinel lymph node in breast cancer. Breast Cancer. 2017;9:325–30. PubMed Petropoulou T, Kapoula A, Mastoraki A, Politi A, Spanidou-Karvouni E, Psychogios I, et al. Imprint cytology versus frozen section analysis for intraoperative assessment of sentinel lymph node in breast cancer. Breast Cancer. 2017;9:325–30. PubMed
43.
Zurück zum Zitat Marano A, Sodano B, Vitiello C, Martini AM, Baldassarre F, Siciliano A, et al. Sentinel lymph node biopsy with intraoperative touch imprint cytology (TIC) in breast cancer: experience of a mild-volume center. G Chir. 2020;41:94. PubMed Marano A, Sodano B, Vitiello C, Martini AM, Baldassarre F, Siciliano A, et al. Sentinel lymph node biopsy with intraoperative touch imprint cytology (TIC) in breast cancer: experience of a mild-volume center. G Chir. 2020;41:94. PubMed
45.
Zurück zum Zitat Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93. PubMedPubMedCentral Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93. PubMedPubMedCentral
46.
Zurück zum Zitat Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. PubMedPubMedCentral Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. PubMedPubMedCentral
49.
Zurück zum Zitat Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220. PubMed Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220. PubMed
51.
Zurück zum Zitat Takei H, Suemasu K, Kurosumi M, Horii Y, Yoshida T, Ninomiya J, et al. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer. 2007;14:16–24. PubMed Takei H, Suemasu K, Kurosumi M, Horii Y, Yoshida T, Ninomiya J, et al. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer. 2007;14:16–24. PubMed
52.
Zurück zum Zitat Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30. PubMed Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30. PubMed
53.
Zurück zum Zitat Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different? Surgery. 2008;143:641–7. PubMed Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different? Surgery. 2008;143:641–7. PubMed
54.
Zurück zum Zitat Spiguel L, Yao K, Winchester DJ, Gorchow A, Du H, Sener SF, et al. Sentinel node biopsy alone for node-positive breast cancer: 12-year experience at a single institution. J Am Coll Surg. 2011;213:122–8. PubMed Spiguel L, Yao K, Winchester DJ, Gorchow A, Du H, Sener SF, et al. Sentinel node biopsy alone for node-positive breast cancer: 12-year experience at a single institution. J Am Coll Surg. 2011;213:122–8. PubMed
55.
Zurück zum Zitat Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS III. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462. PubMedPubMedCentral Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS III. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462. PubMedPubMedCentral
56.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53. PubMed Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53. PubMed
57.
Zurück zum Zitat Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17:343–51. PubMedPubMedCentral Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17:343–51. PubMedPubMedCentral
59.
Zurück zum Zitat Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:423–6. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:423–6.
60.
Zurück zum Zitat Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–26. PubMedPubMedCentral Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–26. PubMedPubMedCentral
61.
Zurück zum Zitat Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10. PubMedPubMedCentral Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10. PubMedPubMedCentral
62.
Zurück zum Zitat Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment Of the Axilla—Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43:672–9. PubMed Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment Of the Axilla—Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43:672–9. PubMed
70.
Zurück zum Zitat Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558–66. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558–66.
72.
Zurück zum Zitat Hamdy O. Neoadjuvant therapy should be the standard of care for every node positive breast cancer patient. J Breast Cancer. 2019;22:149–52. PubMed Hamdy O. Neoadjuvant therapy should be the standard of care for every node positive breast cancer patient. J Breast Cancer. 2019;22:149–52. PubMed
73.
Zurück zum Zitat Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365–83. PubMed Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365–83. PubMed
74.
Zurück zum Zitat Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18.
75.
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61. PubMedPubMedCentral Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61. PubMedPubMedCentral
76.
Zurück zum Zitat Boileau J‑F, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64. Boileau J‑F, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64.
78.
Zurück zum Zitat Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, et al. Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy—results from ACOSOG Z1071. Ann Surg. 2016;263:802. PubMedPubMedCentral Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, et al. Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy—results from ACOSOG Z1071. Ann Surg. 2016;263:802. PubMedPubMedCentral
79.
Zurück zum Zitat Mamounas ETP. Optimal management of the axilla: a look at the evidence. Adv Surg. 2016;50:29–40. PubMed Mamounas ETP. Optimal management of the axilla: a look at the evidence. Adv Surg. 2016;50:29–40. PubMed
82.
Zurück zum Zitat Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378–82. Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378–82.
83.
Zurück zum Zitat van Nijnatten TJA, Simons JM, Smidt ML, van der Pol CC, van Diest PJ, Jager A, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the Axilla with the sentinel node procedure (RISAS): a Dutch pros. Clin Breast Cancer. 2017;17:399–402. PubMedPubMedCentral van Nijnatten TJA, Simons JM, Smidt ML, van der Pol CC, van Diest PJ, Jager A, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the Axilla with the sentinel node procedure (RISAS): a Dutch pros. Clin Breast Cancer. 2017;17:399–402. PubMedPubMedCentral
85.
Zurück zum Zitat Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8. PubMedPubMedCentral Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8. PubMedPubMedCentral
87.
Zurück zum Zitat Natsiopoulos I, Intzes S, Liappis T, Zarampoukas K, Zarampoukas T, Zacharopoulou V, et al. Axillary lymph node tattooing and targeted axillary dissection in breast cancer patients who presented as cN+ before neoadjuvant chemotherapy and became cN0 after treatment. Clin Breast Cancer. 2019;19:208–15. PubMedPubMedCentral Natsiopoulos I, Intzes S, Liappis T, Zarampoukas K, Zarampoukas T, Zacharopoulou V, et al. Axillary lymph node tattooing and targeted axillary dissection in breast cancer patients who presented as cN+ before neoadjuvant chemotherapy and became cN0 after treatment. Clin Breast Cancer. 2019;19:208–15. PubMedPubMedCentral
92.
Zurück zum Zitat de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Ryden L, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379. PubMedPubMedCentral de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Ryden L, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379. PubMedPubMedCentral
95.
Zurück zum Zitat Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21:678–81. PubMed Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21:678–81. PubMed
99.
Zurück zum Zitat Shi F, Zhang Q, Liang Z, Zhang M, Liu X. One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis. Br J Cancer. 2017;117:1185–91. PubMedPubMedCentral Shi F, Zhang Q, Liang Z, Zhang M, Liu X. One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis. Br J Cancer. 2017;117:1185–91. PubMedPubMedCentral
Metadaten
Titel
Sentinel lymph node biopsy in breast cancer—an updated overview
verfasst von
Dr. Omar Hamdy
Omar Farouk
Adel El-Badrawy
Adel Denewer
Ahmed Setit
Publikationsdatum
01.10.2020
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 6/2020
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-020-00665-w